Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cross-sectional, Observational, Multi-center Study to Assess the Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight (rFVIII-Fc, Manufactured by AryoGen Pharmed Co.)

NCT07791836 is registered in ClinicalTrials.gov with AryoGen Pharmed Co. as lead sponsor.

NCT NCT07791836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07791836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cross-sectional, Observational, Multi-center Study to Assess the Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight (rFVIII-Fc, Manufactured by AryoGen Pharmed Co.)
Lead sponsor
AryoGen Pharmed Co.
Phase
Observational
Overall status
Not yet recruiting
Start date
August 23, 2026
Completion date
February 20, 2027
Enrollment
262 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia, hemophilia a